Table 1.

Baseline characteristics of 54 patients who received conversion therapy

Age median (range), yr	65 (35-83)
Male, n (%)	31 (58%)
Platelet count, median (range), 104/μL	19.1 (6.5-37.5)
Total bilirubin, median (range) mg/dL	0.7 (0.3-1.3)
Serum albumin, median (range), g/L	3.9 (3.0-4.4)
Prothrombin activity, median (range), %	108 (54-137)
Serum CEA level, median (range), ng/mL	6.1 (1.0-172.6)
Size of largest tumor, median (range), mm	25.5 (5-160)
Tumor number, median (range)	2.5 (1-19)
Synchronous/Metachronous	34/19
Molecular targets (present), n (%)	27 (50%)
Chemotherapy cycles, median (range)	6 (2-38)
RECIST CR/PR/SD/PD	2/32/15/5

CEA, carcinoembryonic antigen; RECIST, response evaluation criteria in solid tumors (version 1.1).